Clinical trials: Organ Preservation, open to volunteers
Esophageal Squamous Cell Carcinoma
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete…
- Trial name
- WATCHER (NCT05507411)
- Testing
- Neoadjuvant Radiotherapy, Neoadjuvant Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Rectal Cancer
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
This trial is a multicenter randomized Phase III study to verify the superiority of short-course preoperative radiation (SCRT) and CAPOXIRI over SCRT and CAPOX as preoperative treatments for locally advanced rectal cancer.
- Trial name
- ENSEMBLE (NCT05646511)
- Testing
- SCRT, CAPOX, CAPOXIRI
- Where
- 34 sites in Japan
- Volunteers
- 608 people
- Sponsor
- National Cancer Center Hospital East
Esophageal Squamous Cell Carcinoma
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell…
- Trial name
- HCHTOG2603 (NCT07629817)
- Testing
- Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy, Radiation with Concurrent Chemotherapy, Radical Esophagectomy
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Henan Cancer Hospital
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
This pilot trial studies how well active surveillance and chemotherapy before surgery work in treating participants with stage II-III rectal cancer.
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8
- Trial name
- NCT03594630
- Testing
- Chemotherapy, Patient Observation, Questionnaire Administration
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer, Rectum Neoplasm
Local Excision for Organ Preservation in Early REctal Cancer With No Adjuvant Treatment
Rectal cancer is one of the most frequent malignant tumors nowadays. There are several possible treatment options including chemotherapy, radiotherapy and surgery.
- Trial name
- LORENA (NCT05927584)
- Testing
- Transanal local excision
- Where
- Spain
- Volunteers
- 145 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Towards Cure Via Only Ultra-short ICB in CSCC
The goal of this clinical trial is to determine whether cutaneous squamous cell carcinoma patients can be cured using only immunotherapy, without surgery or radiotherapy.
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Cutaneous Squamous Cell Carcinoma
- Trial name
- MATISSE 2 (NCT06823479)
- Testing
- Nivolumab, Ipilumimab
- Where
- 5 sites in Netherlands
- Volunteers
- 41 people
- Sponsor
- The Netherlands Cancer Institute
Urothelial Carcinoma Bladder
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries.
- Trial name
- NCT06184516
- Testing
- Reproductive organ sparing radical cystectomy, Radical cystectomy
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of Florida
Transplant; Complication, Failure
Evaluation at 5 and 10 Years of Renal Transplant Patients
5 and 10 years follow-up of the oxyop study.
- Trial name
- OXYOP 5 and 10 (NCT05469906)
- Where
- France
- Volunteers
- 116 people
- Sponsor
- University Hospital, Brest
Colorectal Cancer
T1 Colorectal Cancer After Local Excision: Decision Between Surgery and Active Surveillance (T1LDA Trial)
The goal of this two-arm clinical trial is to compare additional surgery with active surveillance in patients with high-risk pT1 colorectal cancer after local excision.
- Trial name
- T1LDA (NCT07900620)
- Testing
- Additional surgery
- Where
- 14 sites in Finland
- Volunteers
- 500 people
- Sponsor
- Tampere University Hospital
Early Gastric Cancer
LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
Early gastric cancer (EGC) is traditionally treated with either endoscopic resection or standard laparoscopic gastrectomy with formal lymph node dissection.
- Trial name
- LENS (NCT07857668)
- Testing
- Procedure: LECS combined with LSNNS
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Colorectal Carcinoma
Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)
The combination of preoperative pelvic RT - either long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT)- followed by surgery has been the standard of care in the curative treatment of locally advanced…
- Trial name
- Hypo-OPRA (NCT06991465)
- Testing
- Radiation Therapy, FOLFOX regimen, Capecitabine
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Neil Kopek
Organ Preservation, Rectal Cancer Stage I
Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer
Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized…
- Conditions
- Organ Preservation, Rectal Cancer Stage I, Total Neoadjuvant Treatment, Consolidation Therapy
- Trial name
- OPTION (NCT07563907)
- Testing
- TNT with additional consolidation chemotherapy followed by local excision, TNT followed by local excision
- Where
- South Korea
- Volunteers
- 292 people
- Sponsor
- Seoul National University Hospital
LOCALLY ADVANCED RECTAL CANCER
Organ Preservation in Locally Advanced Rectal Cancer
PRONAR trial aims to assess if treatment with organ preservation in stage II and III rectal cancer after a complete or almost complete response to neoadjuvant treatment is feasible and safe in our environment.
- Trial name
- PRONAR (NCT03064646)
- Testing
- Organ Preservation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
End-stage Liver Disease (ESLD), Acute Liver Failure
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given…
- Conditions
- End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
- Trial name
- REFRAME-MP (NCT07585890)
- Testing
- Endischemic hypothermic oxygenated machine perfusion (any device), Endischemic (back-to-base) normothermic machine perfusion (any device), Continuous (device-to-donor) normothermic machine perfusion (any device)
- Where
- 38 sites in Austria, Belgium and 8 more
- Volunteers
- 10,000 people
- Sponsor
- University Medical Center Groningen
Gastrointestinal Cancer, Gastric Cancer
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers
The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy…
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer
- Trial name
- NOMAD-GI (NCT07775859)
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer, Radiation Oncology
Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients
The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.
- Trial name
- REBOOT (NCT07616297)
- Testing
- Simultaneous integrated boost to the tumor and positive mesorectal lymph nodes
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Claudia Schuurhuizen
Gastrointestinal Cancers, Gastrointestinal Cancers - Stomach
Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers
Purpose: The purpose of this study is to evaluate the safety and efficacy of Non-Operative Management (NOM) and Organ Preservation First Strategy (OPFS) compared with Radical Operation (RO) in patients with deficient mismatch…
- Conditions
- Gastrointestinal Cancers, Gastrointestinal Cancers - Stomach, Gastrointestinal Cancers - Colorectal, Gastrointestinal Cancers - Anus
- Trial name
- NOR-MP (NCT07642323)
- Testing
- NOM/OPFS
- Volunteers
- 22 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
This is a multicenter phase II clinical study to explore the efficacy, safety, and organ preservation feasibility of camrelizumab in combination with chemotherapy for resectable esophageal squamous carcinoma in patients with…
- Trial name
- NCT06869226
- Testing
- Camrelizumab + Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 283 people
- Sponsor
- Peking University Cancer Hospital & Institute
Gastroesophageal Adenocarcinoma
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
This study will test a new personalized treatment approach for patients with stomach or esophageal cancer. It will take place in two stages and aims to find the best combination of chemotherapy, immunotherapy, and targeted drugs…
- Trial name
- AACR-ADOPT-GEA (NCT07290985)
- Testing
- Tislelizumab, Leucovorin, Oxaliplatin
- Where
- 4 sites in United States, Canada
- Volunteers
- 242 people
- Sponsor
- American Association for Cancer Research
Phase 2 Study
mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer
Neoadjuvant mFOLFOXIRI plus bevacizumab may achieve tumor shrinkage and reduce micrometastases, offering a radiotherapy-free organ-preservation alternative for locally advanced rectal cancer.
- Trial name
- FOBEAR-ii (NCT07817888)
- Testing
- FOLFOXIRI + Bevacizumab
- Volunteers
- 119 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University